Unknown

Dataset Information

0

A Novel Cu(II)-Binding Peptide Identified by Phage Display Inhibits Cu2+-Mediated Aβ Aggregation.


ABSTRACT: Copper (Cu) has been implicated in the progression of Alzheimer's disease (AD), and aggregation of Cu and amyloid β peptide (Aβ) are considered key pathological features of AD. Metal chelators are considered to be potential therapeutic agents for AD because of their capacity to reduce metal ion-induced Aβ aggregation through the regulation of metal ion distribution. Here, we used phage display technology to screen, synthesize, and evaluate a novel Cu(II)-binding peptide that specifically blocked Cu-triggered Aβ aggregation. The Cu(II)-binding peptide (S-A-Q-I-A-P-H, PCu) identified from the phage display heptapeptide library was used to explore the mechanism of PCu inhibition of Cu2+-mediated Aβ aggregation and Aβ production. In vitro experiments revealed that PCu directly inhibited Cu2+-mediated Aβ aggregation and regulated copper levels to reduce biological toxicity. Furthermore, PCu reduced the production of Aβ by inhibiting Cu2+-induced BACE1 expression and improving Cu(II)-mediated cell oxidative damage. Cell culture experiments further demonstrated that PCu had relatively low toxicity. This Cu(II)-binding peptide that we have identified using phage display technology provides a potential therapeutic approach to prevent or treat AD.

SUBMITTER: Zhang X 

PROVIDER: S-EPMC8269028 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4687576 | biostudies-literature
| S-EPMC3013143 | biostudies-literature
| S-EPMC5342741 | biostudies-literature
| S-EPMC2651023 | biostudies-literature
| S-EPMC7860060 | biostudies-literature
| S-EPMC5961013 | biostudies-literature
| S-EPMC1183247 | biostudies-literature
| S-EPMC8340127 | biostudies-literature
| S-EPMC3044727 | biostudies-literature
| S-EPMC4417150 | biostudies-other